Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Chiara Scoccianti is active.

Publication


Featured researches published by Chiara Scoccianti.


The New England Journal of Medicine | 2016

Body Fatness and Cancer — Viewpoint of the IARC Working Group

Béatrice Lauby-Secretan; Chiara Scoccianti; Dana Loomis; Franca Bianchini; Kurt Straif

The International Agency for Research on Cancer convened a workshop on the relationship between body fatness and cancer, from which an IARC handbook on the topic will appear. An executive summary of the evidence is presented.


The New England Journal of Medicine | 2015

Breast-Cancer Screening — Viewpoint of the IARC Working Group

Béatrice Secretan; Chiara Scoccianti; Dana Loomis; Lamia Benbrahim‑Tallaa; Véronique Bouvard; Franca Bianchini; Kurt Straif

The International Agency for Research on Cancer (IARC) has updated its 2002 guidelines on screening for breast cancer, drawing on data from studies completed in the past 15 years.


Lancet Oncology | 2015

Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate

Kathryn Z. Guyton; Dana Loomis; Fatiha El Ghissassi; Lamia Benbrahim-Tallaa; Neela Guha; Chiara Scoccianti; Heidi Mattock; Kurt Straif

DOI: http://dx.doi.org/10.1016/S1470-2045(15)70134-8 Article Info  Summary  Full Text  Tables and Figures  References In March, 2015, 17 experts from 11 countries met at the International Agency for Research on Cancer (IARC; Lyon, France) to assess the carcinogenicity of the organophosphate pesticides tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate (table). These assessments will be published as volume 112 of the IARC Monographs.


American Journal of Preventive Medicine | 2014

Female Breast Cancer and Alcohol Consumption: A Review of the Literature

Chiara Scoccianti; Béatrice Lauby-Secretan; Pierre-Yves Bello; Véronique Chajès; Isabelle Romieu

CONTEXT Consumption of alcoholic beverages is one of the single most important known and modifiable risk factor for human cancer. Among women, breast cancer is the most common cancer worldwide and the leading cause of cancer-related mortality. Consumption of alcoholic beverages is causally associated with female breast cancer and the association shows a linear dose-response relationship. The role of heavy drinking has been long recognized and even a moderate intake is associated with an increased risk for breast cancer. The present review is an update of the current evidence on the association between alcohol consumption and breast cancer risk. The aim is to gain further insight into this association and to improve our current understanding of the effects of the major modifying factors. EVIDENCE ACQUISITION Epidemiologic and experimental studies published since the most recent International Agency for Research on Cancer (IARC) Monograph on alcoholic beverages were identified in PubMed using a combination of keywords such as alcohol, breast cancer, polymorphisms, menopausal status. EVIDENCE SYNTHESIS Cumulative lifetime consumption, drinking frequency, drinking patterns and timing of exposure each modulate the association between alcohol consumption and breast cancer. Hormonal status, genetic polymorphisms, and nutritional factors may interact with ethanol metabolism and further influence breast cancer risk. CONCLUSIONS Better standardization among experimental and epidemiologic designs in assessing alcohol intake and timing of exposure may improve our understanding of the heterogeneity observed across studies, possibly allowing the quantification of the effects of occasional heavy drinking and the identification of a window of higher susceptibility to breast cancer development.


Cancer Epidemiology | 2015

European Code against Cancer 4th Edition: Diet and cancer

Teresa Norat; Chiara Scoccianti; Marie Christine Boutron-Ruault; Annie S. Anderson; Franco Berrino; Michele Cecchini; Carolina Espina; Timothy J. Key; Michael F. Leitzmann; Hilary J. Powers; Martin Wiseman; Isabelle Romieu

Lifestyle factors, including diet, have long been recognised as potentially important determinants of cancer risk. In addition to the significant role diet plays in affecting body fatness, a risk factor for several cancers, experimental studies have indicated that diet may influence the cancer process in several ways. Prospective studies have shown that dietary patterns characterised by higher intakes of fruits, vegetables, and whole-grain foods, and lower intakes of red and processed meats and salt, are related to reduced risks of death and cancer, and that a healthy diet can improve overall survival after diagnosis of breast and colorectal cancers. There is evidence that high intakes of fruit and vegetables may reduce the risk of cancers of the aerodigestive tract, and the evidence that dietary fibre protects against colorectal cancer is convincing. Red and processed meats increase the risk of colorectal cancer. Diets rich in high-calorie foods, such as fatty and sugary foods, may lead to increased calorie intake, thereby promoting obesity and leading to an increased risk of cancer. There is some evidence that sugary drinks are related to an increased risk of pancreatic cancer. Taking this evidence into account, the 4th edition of the European Code against Cancer recommends that people have a healthy diet to reduce their risk of cancer: they should eat plenty of whole grains, pulses, vegetables and fruits; limit high-calorie foods (foods high in sugar or fat); avoid sugary drinks and processed meat; and limit red meat and foods high in salt.


Cancer Epidemiology | 2015

European Code against Cancer 4th Edition: Physical activity and cancer.

Michael F. Leitzmann; Hilary J. Powers; Annie S. Anderson; Chiara Scoccianti; Franco Berrino; Marie Christine Boutron-Ruault; Michele Cecchini; Carolina Espina; Timothy J. Key; Teresa Norat; Martin Wiseman; Isabelle Romieu

Physical activity is a complex, multidimensional behavior, the precise measurement of which is challenging in free-living individuals. Nonetheless, representative survey data show that 35% of the European adult population is physically inactive. Inadequate levels of physical activity are disconcerting given substantial epidemiologic evidence showing that physical activity is associated with decreased risks of colon, endometrial, and breast cancers. For example, insufficient physical activity levels are thought to cause 9% of breast cancer cases and 10% of colon cancer cases in Europe. By comparison, the evidence for a beneficial effect of physical activity is less consistent for cancers of the lung, pancreas, ovary, prostate, kidney, and stomach. The biologic pathways underlying the association between physical activity and cancer risk are incompletely defined, but potential etiologic pathways include insulin resistance, growth factors, adipocytokines, steroid hormones, and immune function. In recent years, sedentary behavior has emerged as a potential independent determinant of cancer risk. In cancer survivors, physical activity has shown positive effects on body composition, physical fitness, quality of life, anxiety, and self-esteem. Physical activity may also carry benefits regarding cancer survival, but more evidence linking increased physical activity to prolonged cancer survival is needed. Future studies using new technologies - such as accelerometers and e-tools - will contribute to improved assessments of physical activity. Such advancements in physical activity measurement will help clarify the relationship between physical activity and cancer risk and survival. Taking the overall existing evidence into account, the fourth edition of the European Code against Cancer recommends that people be physically active in everyday life and limit the time spent sitting.


European Respiratory Journal | 2012

Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: The EUELC cohort

Chiara Scoccianti; Aurélien Vesin; Ghislaine Martel; Magali Olivier; Elisabeth Brambilla; Jean-François Timsit; Luca Tavecchio; Christian Brambilla; John K. Field; Pierre Hainaut

Nonsmall cell lung cancer samples from the European Early Lung Cancer biobank were analysed to assess the prognostic significance of mutations in the TP53, KRAS and EGFR genes. The series included 11 never-smokers, 86 former smokers, 152 current smokers and one patient without informed smoking status. There were 110 squamous cell carcinomas (SCCs), 133 adenocarcinomas (ADCs) and seven large cell carcinomas or mixed histologies. Expression of p53 was analysed by immunohistochemistry. DNA was extracted from frozen tumour tissues. TP53 mutations were detected in 48.8% of cases and were more frequent among SCCs than ADCs (p<0.0001). TP53 mutation status was not associated with prognosis. G to T transversions, known to be associated with smoking, were marginally more common among patients who developed a second primary lung cancer or recurrence/metastasis (progressive disease). EGFR mutations were almost exclusively found in never-smoking females (p=0.0067). KRAS mutations were detected in 18.5% of cases, mainly ADC (p<0.0001), and showed a tendency toward association with progressive disease status. These results suggest that mutations are good markers of different aetiologies and histopathological forms of lung cancers but have little prognostic value, with the exception of KRAS mutation, which may have a prognostic value in ADC.


Cancer Epidemiology, Biomarkers & Prevention | 2010

Plasma Cytokines and Future Risk of Non-Hodgkin Lymphoma (NHL): A Case-Control Study Nested in the Italian European Prospective Investigation into Cancer and Nutrition

Fatemaeh Saberi Hosnijeh; Esmeralda Krop; Chiara Scoccianti; Vittorio Krogh; Domenico Palli; Salvatore Panico; Rosario Tumino; Carlotta Sacredote; Niga Nawroly; Lützen Portengen; Jakob Linseisen; Paolo Vineis; Roel Vermeulen

Background: Recently, biological markers related to the immune system such as cytokines have been studied to further understand the etiology of non-Hodgkin Lymphoma (NHL). However, to date, there are no studies that have studied cytokine levels prospectively in relation to NHL risk in the general population. Methods: Using bead-based immunoassays, plasma levels of 11 cytokines, 4 chemokines, and 1 adhesion molecules were measured in prediagnostic blood samples of 86 NHL cases and 86 matched controls (average time between blood collection and diagnosis, 4.5 y). Conditional logistic regression adjusted for body mass index and alcohol consumption was used to analyze the association between individual plasma cytokine levels and the risk of developing NHL. Results: In multivariate models, excluding cases diagnosed within 2 years after inclusion, we observed a significant association for interleukin 2 (IL2; P trend = 0.004), interferon (IFN)-γ (P trend = 0.05), and intercellular adhesion molecule (ICAM) (P trend = 0.04). Subanalyses of B-cell NHL patients showed a significant association with IL2 (P trend = 0.003), tumor necrosis factor-α (TNF-α; P trend = 0.03), and ICAM (P trend = 0.04) and a borderline association with IL5 (P trend = 0.07) and IFN-γ (P trend = 0.08). Conclusions: The results of this study suggest, in a prospective setting, a possible association between plasma levels of IL2, ICAM, IFN-γ, and TNF-α with NHL risk and provide some evidence that risk of NHL might be related to a downregulation of T helper 1 cytokines. Impact: Identification of subtle changes in immune response regulation quantified by plasma cytokine levels possibly provides new insights in the etiology of NHL. Cancer Epidemiol Biomarkers Prev; 19(6); 1577–84. ©2010 AACR.


Cancer Epidemiology | 2015

European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk

Joachim Schüz; Carolina Espina; Patricia Villain; Rolando Herrero; Maria E. Leon; Silvia Minozzi; Isabelle Romieu; Nereo Segnan; Jane Wardle; Martin Wiseman; Filippo Belardelli; Douglas Bettcher; Franco Cavalli; Gauden Galea; Gilbert M. Lenoir; Jose M. Martin-Moreno; Florian Alexandru Nicula; Jørgen H. Olsen; Julietta Patnick; Maja Primic-Zakelj; Pekka Puska; Flora E. van Leeuwen; Otmar D. Wiestler; Witold Zatonski; Neela Guha; Eva Kralikova; Anne McNeill; Armando Peruga; Annie S. Anderson; Franco Berrino

This overview describes the principles of the 4th edition of the European Code against Cancer and provides an introduction to the 12 recommendations to reduce cancer risk. Among the 504.6 million inhabitants of the member states of the European Union (EU28), there are annually 2.64 million new cancer cases and 1.28 million deaths from cancer. It is estimated that this cancer burden could be reduced by up to one half if scientific knowledge on causes of cancer could be translated into successful prevention. The Code is a preventive tool aimed to reduce the cancer burden by informing people how to avoid or reduce carcinogenic exposures, adopt behaviours to reduce the cancer risk, or to participate in organised intervention programmes. The Code should also form a base to guide national health policies in cancer prevention. The 12 recommendations are: not smoking or using other tobacco products; avoiding second-hand smoke; being a healthy body weight; encouraging physical activity; having a healthy diet; limiting alcohol consumption, with not drinking alcohol being better for cancer prevention; avoiding too much exposure to ultraviolet radiation; avoiding cancer-causing agents at the workplace; reducing exposure to high levels of radon; encouraging breastfeeding; limiting the use of hormone replacement therapy; participating in organised vaccination programmes against hepatitis B for newborns and human papillomavirus for girls; and participating in organised screening programmes for bowel cancer, breast cancer, and cervical cancer.


International Journal of Cancer | 2015

Alcohol intake and breast cancer in the European prospective investigation into cancer and nutrition

Isabelle Romieu; Chiara Scoccianti; Véronique Chajès; Jordi de Batlle; Carine Biessy; Laure Dossus; Laura Baglietto; Françoise Clavel-Chapelon; Kim Overvad; Anja Olsen; Anne Tjønneland; Rudolf Kaaks; Annekatrin Lukanova; Heiner Boeing; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Domenico Palli; Sabina Sieri; Rosario Tumino; Paolo Vineis; Salvatore Panico; H. Bas Bueno-de-Mesquita; Carla H. van Gils; Petra H. Peeters; Eiliv Lund; Guri Skeie; Elisabete Weiderpass; Jose Ramon Quiros Garcia; Maria Dolores Chirlaque

Alcohol intake has been associated to breast cancer in pre and postmenopausal women; however results are inconclusive regarding tumor hormonal receptor status, and potential modifying factors like age at start drinking. Therefore, we investigated the relation between alcohol intake and the risk of breast cancer using prospective observational data from the European Prospective Investigation into Cancer and Nutrition (EPIC). Up to 334,850 women, aged 35–70 years at baseline, were recruited in ten European countries and followed up an average of 11 years. Alcohol intake at baseline and average lifetime alcohol intake were calculated from country‐specific dietary and lifestyle questionnaires. The study outcomes were the Hazard ratios (HR) of developing breast cancer according to hormonal receptor status. During 3,670,439 person‐years, 11,576 incident breast cancer cases were diagnosed. Alcohol intake was significantly related to breast cancer risk, for each 10 g/day increase in alcohol intake the HR increased by 4.2% (95% CI: 2.7–5.8%). Taking 0 to 5 g/day as reference, alcohol intake of >5 to 15 g/day was related to a 5.9% increase in breast cancer risk (95% CI: 1–11%). Significant increasing trends were observed between alcohol intake and ER+/PR+, ER−/PR−, HER2− and ER−/PR−HER2− tumors. Breast cancer risk was stronger among women who started drinking prior to first full‐time pregnancy. Overall, our results confirm the association between alcohol intake and both hormone receptor positive and hormone receptor negative breast tumors, suggesting that timing of exposure to alcohol drinking may affect the risk. Therefore, women should be advised to control their alcohol consumption.

Collaboration


Dive into the Chiara Scoccianti's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paolo Vineis

Imperial College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martin Wiseman

Southampton General Hospital

View shared research outputs
Top Co-Authors

Avatar

Franco Berrino

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Carolina Espina

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Michele Cecchini

Organisation for Economic Co-operation and Development

View shared research outputs
Top Co-Authors

Avatar

Rosario Tumino

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Véronique Chajès

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Salvatore Panico

University of Naples Federico II

View shared research outputs
Researchain Logo
Decentralizing Knowledge